The imbalance of intestinal microbiota is closely related to digestive system diseases. Microecological therapy targeting the structure and function of intestinal microbiota has become a strategy. The artificial flora designed and synthesized with the concept of synthetic biology is expected to overcome the existed shortcomings and achieve high efficiency, precision and control of microecological therapy. Engineered probiotics are the next generation of live biotherapeutics that have been modified to target specific diseases.
Identifying and isolating microbes within intestinal microbiota that can interact with probiotics provides an important basis for evaluating the efficacy of probiotics and the underlining mechanisms. Currently, conventional culture methods remain the mainstream approach in the microbiology community. However, emerging technologies, such as Raman spectroscopy and microfluidic technologies, have provided powerful tools to study microbiome function at the single-cell level. We anticipate these advancements will significantly improve our ability to investigate how probiotics interact with the native microbiota and understand their therapeutical roles.
This Research Topic focuses on the development of multidisciplinary methods and devices, including but not limited to gene editing, chemical modification, and the single-cell technology, in engineering and evaluating probiotics as potential therapeutical agents to treat intestinal diseases such as inflammatory bowel disease (IBD), related colorectal cancer (CRC), colonic constipation, diarrhea, irritable bowel syndrome(IBS), acute or chronic radiation enteropathy.
This Research Topic welcomes Original Research and Review articles on, but not limited to, the following areas:
• Metabolic engineering of probiotics for improving the synthetic capability of desired products such as SCFAs, Vitamins and active ingredients from botanical sources.
• Development and optimization of genetic editing tools in probiotics for the next generation of live biotherapeutics.
• Use material methods or chemical strategies to modify probiotics for achieving therapeutic purposes in major diseases.
• Novel tools, such as microfluidics and single-cell technology, are being developed to evaluate the efficiency of biotherapeutics and study mechanisms of host-bacterial interactions.
The imbalance of intestinal microbiota is closely related to digestive system diseases. Microecological therapy targeting the structure and function of intestinal microbiota has become a strategy. The artificial flora designed and synthesized with the concept of synthetic biology is expected to overcome the existed shortcomings and achieve high efficiency, precision and control of microecological therapy. Engineered probiotics are the next generation of live biotherapeutics that have been modified to target specific diseases.
Identifying and isolating microbes within intestinal microbiota that can interact with probiotics provides an important basis for evaluating the efficacy of probiotics and the underlining mechanisms. Currently, conventional culture methods remain the mainstream approach in the microbiology community. However, emerging technologies, such as Raman spectroscopy and microfluidic technologies, have provided powerful tools to study microbiome function at the single-cell level. We anticipate these advancements will significantly improve our ability to investigate how probiotics interact with the native microbiota and understand their therapeutical roles.
This Research Topic focuses on the development of multidisciplinary methods and devices, including but not limited to gene editing, chemical modification, and the single-cell technology, in engineering and evaluating probiotics as potential therapeutical agents to treat intestinal diseases such as inflammatory bowel disease (IBD), related colorectal cancer (CRC), colonic constipation, diarrhea, irritable bowel syndrome(IBS), acute or chronic radiation enteropathy.
This Research Topic welcomes Original Research and Review articles on, but not limited to, the following areas:
• Metabolic engineering of probiotics for improving the synthetic capability of desired products such as SCFAs, Vitamins and active ingredients from botanical sources.
• Development and optimization of genetic editing tools in probiotics for the next generation of live biotherapeutics.
• Use material methods or chemical strategies to modify probiotics for achieving therapeutic purposes in major diseases.
• Novel tools, such as microfluidics and single-cell technology, are being developed to evaluate the efficiency of biotherapeutics and study mechanisms of host-bacterial interactions.
